New triplet therapy targets tough bladder cancer in small trial
NCT ID NCT05335941
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 23 times
Summary
This study tests a combination of three drugs (pemetrexed, etrumadenant, and zimberelimab) in 10 adults with advanced bladder cancer that has a specific genetic change called MTAP deficiency. All participants had prior immunotherapy that stopped working. The goal is to see if this triple therapy can shrink tumors and control the disease, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.